We are live on ! Find out more
CADL icon

Candel Therapeutics
CADL

25 hedge funds and large institutions have $19.1M invested in Candel Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 3

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

9% more funds holding

Funds holding: 23 → 25 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1.07% less ownership

Funds ownership: 22.12% → 21.05% (-1.1%)

7% less capital invested

Capital invested by funds: $20.6M → $19.1M (-$1.46M)

Holders
25
Holders Change
+2
Holders Change %
+8.7%
% of All Funds
0.43%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
7
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$182K
2
Citadel Advisors
Citadel Advisors
Florida
+$57.1K
3
Millennium Management
Millennium Management
New York
+$50.3K
4
TRCT
Tower Research Capital (TRC)
New York
+$9.89K
5
Morgan Stanley
Morgan Stanley
New York
+$2.23K

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.15M
2
Goldman Sachs
Goldman Sachs
New York
-$33K
3
BlackRock
BlackRock
New York
-$14.9K
4
PHK
Point72 Hong Kong
Hong Kong
-$2K
5
Citigroup
Citigroup
New York
-$322
Name Holding Trade Value Shares
Change 		Change in
Stake
NV
1
Northpond Ventures
Maryland
$6.08M – – –
Franklin Resources
2
Franklin Resources
California
$3.53M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$2.82M – – –
SCV
4
Sands Capital Ventures
Virginia
$2.55M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.27M – – –
Point72 Asset Management
6
Point72 Asset Management
Connecticut
$1.27M -$1.15M -339,951 -46%
BCM
7
Bridgeway Capital Management
Texas
$417K – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$404K +$182K +53,629 +71%
BlackRock
9
BlackRock
New York
$393K -$14.9K -4,407 -3%
State Street
10
State Street
Massachusetts
$87K – – –
Citadel Advisors
11
Citadel Advisors
Florida
$53K +$57.1K +16,851 New
Millennium Management
12
Millennium Management
New York
$47K +$50.3K +14,844 New
Northern Trust
13
Northern Trust
Illinois
$45K – – –
KAS
14
Kestra Advisory Services
Texas
$39K – – –
EAM
15
Empirical Asset Management
Massachusetts
$38K – – –
Morgan Stanley
16
Morgan Stanley
New York
$17K +$2.23K +659 +14%
UBS Group
17
UBS Group
Switzerland
$13K +$1.27K +374 +10%
TRCT
18
Tower Research Capital (TRC)
New York
$13K +$9.89K +2,918 +239%
JP Morgan Chase
19
JP Morgan Chase
New York
$5K +$715 +211 +17%
BNP Paribas Financial Markets
20
BNP Paribas Financial Markets
France
$1.29K +$1.39K +410 New
Citigroup
21
Citigroup
New York
$1K -$322 -95 -22%
QC
22
Quent Capital
New York
$1K – – –
CUAMC
23
China Universal Asset Management Company
China
$1K +$918 +271 New
Goldman Sachs
24
Goldman Sachs
New York
– -$33K -10,037 Closed
PHK
25
Point72 Hong Kong
Hong Kong
– -$2K -640 Closed
1
2

CADL Hedge Fund Activity: Q3 2022 in Review

25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q3 2022, worth a combined $19.1M — down 7.1% from $20.6M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new CADL positions and 2 closed out — a net gain of 2 holders — while 7 added to existing stakes and 3 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $182K. The largest seller was Point72 Asset Management, cutting an estimated $1.15M.

  • 25 institutional investors held Candel Therapeutics (CADL) as of Q3 2022, up from 23 in Q2 2022.
  • Funds reported $19.1M of Candel Therapeutics stock for Q3 2022, down 7.1% quarter-over-quarter.
  • 4 funds opened new Candel Therapeutics positions in Q3 2022 and 2 closed out, a net change of +2 holders.
  • The largest Candel Therapeutics buyer in Q3 2022 was Geode Capital Management, an estimated $182K added.
  • The largest Candel Therapeutics seller in Q3 2022 was Point72 Asset Management, an estimated $1.15M sold.

Based on aggregated 13F filings for Q3 2022.